MED12 mutations are reported not just in benign uterine neoplasms but also in highly aggressive leiomyosarcomas (Markowski et al., 2012; Mäkinen et al., 2014b; Sadeghi et al., 2016; Yoon et al., 2017; Lee et al., 2018). This evidence concerns the gene MED12 and leiomyosarcoma.